A phase 3 multi-centre randomised placebo-controlled study of azithromycin in the promary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis.
Why are we doing the COMBAT study?
The purpose of this study is to see if we can prevent or delay the onset of lung disease in children with CF by giving them Azithromycin from when they are very young.
What is Azithromycin?
Azithromycin is a medicine that is normally used to treat infections in the body that are caused by bacteria.
What do we already know about Azithromycin?
When researchers gave Azithromycin to older children and adults with CF they discovered that it helped their lung health.
What is bronchiectasis?
Some clinical trials words explained
Who is participating in the COMBAT study?
- Princess Margaret Hospital, Perth WA
- Royal Children's Hospital, Melbourne Vic
- Royal Children's Hospital, Brisbane Qld
- Mater Children's Hospital, Brisbane Qld
- Westmead Children's Hospital, Sydney NSW
- Sydney Children's Hospital, Sydney NSW
- Monash Medical Centre, Melbourne Vic
- Adelaide Woman's and Children's Hospital, Adelaide SA
- Starship Children's Hospital, Auckland New Zealand
Please check in regularly to see our recruitment progress
Hear from families participating in the COMBAT study
Find our what Informed Consent means